Atlas Trials

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Clinical trial NCT04442347 · COMPLETED

Trial details

NCT number
NCT04442347
Sponsor
Arcturus Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Ornithine Transcarbamylase Deficiency
Start date
2020-11-03
Primary completion
2023-08-30
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.